The Scorecard: 1 Month Update: OI Sell — Correct so far

Revisiting our Sell call on OI: entry $6.79, latest $6.53, -3.8%.

This is a Scorecard review, revisiting a past LF0 research call against what actually happened.

Ticker: OI Rating: Sell Published: 2026-08-14 Checkpoint: 2026-09-14 Entry price: $6.79 Latest price: $6.53 as of 2026-09-14 Stock return since entry: -3.8% Signal return: +3.8% Verdict: Correct so far

This is the 1-month checkpoint for this call. LF0 publishes monthly Scorecard updates through month 6, using the closest available daily close on or before the checkpoint date.

Read the original LF0 analysis

What I Said

I rated OI a sell because I thought the balance sheet was still too stretched for the earnings profile: net debt/EBITDA was 5.1x, earnings were still deeply negative, and the company was relying on Fit to Win to do a lot of the heavy lifting. I also pointed out that the stock already looked cheap on EV/EBITDA and EV/revenue, so my case was not valuation alone but that the operating reset had not yet shown up clearly enough to justify the leverage.

I said I would only get more constructive if leverage fell below 4.5x, or if Fit to Win delivered enough cumulative benefit and margin improvement to show the cost base was truly resetting.

Peer Comparison

CompanyReturn Since Entry
OI (this call)-3.8%
BALL-1.7%
CCK-5.4%
GEF-5.6%
GPK-15.2%
SLGN-7.8%

Why It’s Working (Or Not)

So far, following my sell call would have earned 3.8%, which means the short side has worked in the direction I expected. OI has moved lower while the peer group has also been mostly down, so the stock has not been an isolated outlier, but it has still drifted in the bearish direction I was looking for. The specific concern I raised about leverage and weak earnings has not been disproven yet; I have not seen evidence in this review window that net debt/EBITDA has fallen below my 4.5x threshold or that the operating reset has clearly changed the story. That said, the move is modest, so I would not call this a decisive validation of the thesis yet.

What Could Still Prove Me Wrong

I would be wrong if OI starts showing the kind of deleveraging I said I needed to see, especially if net debt/EBITDA moves below 4.5x without a deterioration in cash generation. I would also have to reconsider if Fit to Win begins translating into visibly better margins and earnings, rather than just restructuring activity, because my original concern was that the cost reset had not shown up cleanly in the numbers. If demand softens further and leverage does not improve, that would support my thesis rather than break it.

The August 2026 Cohort

Other directional calls published the same month:

TickerRatingEntryLatestStock ReturnSignal ReturnVerdict
SDGRSell$17.40$19.07+9.6%-9.6%Incorrect so far
VNOMSell$41.67$45.45+9.1%-9.1%Incorrect so far
WGSSell$77.88$83.88+7.7%-7.7%Incorrect so far
ALTSell$3.15$3.32+5.2%-5.2%Incorrect so far
GTNSell$4.91$4.95+0.8%-0.8%Incorrect so far
AESSell$14.71$14.82+0.7%-0.7%Incorrect so far
BASell$210.46$209.24-0.6%+0.6%Correct so far
SPHRSell$147.34$143.54-2.6%+2.6%Correct so far
STXSSell$1.39$1.34-4.0%+4.0%Correct so far
PENNSell$18.56$17.80-4.1%+4.1%Correct so far
LHXSell$260.92$249.68-4.3%+4.3%Correct so far
NNDMSell$1.65$1.54-6.7%+6.7%Correct so far
ADTNSell$7.76$7.21-7.1%+7.1%Correct so far
NUTXBuy$188.41$206.69+9.7%+9.7%Correct so far
NXESell$10.40$9.36-10.0%+10.0%Correct so far
SRGStrong Sell$2.11$1.89-10.4%+15.6%Correct so far
RRGBSell$9.51$7.75-18.5%+18.5%Correct so far
LRCXSell$343.84$279.41-18.7%+18.7%Correct so far
OWLTSell$5.81$4.67-19.6%+19.6%Correct so far

Live LF0 scorecard: The Scorecard | Research Performance dashboard

Past performance does not guarantee future results. Nothing here is investment advice or a recommendation to buy or sell securities. Returns use LF0’s daily-close scorecard methodology.

Research disclaimer

This material is provided for research and educational purposes only. It is not investment advice, a recommendation, or an offer to buy or sell any security or strategy.

New stock analysis in your inbox.

Independent equity research on under-the-radar companies from lf0 — free, when new work publishes.




No spam. Unsubscribe anytime.

Prefer Substack? Follow lf0 Research on Substack

Leave a Comment

Your email address will not be published. Required fields are marked *